Uppsala, September 13, 2023. OssDsign AB (publ.) at this time publicizes that the corporate’s orthobiologic enterprise continues to speed up its profitable commercialization within the U.S. To at the present time, 2,000 sufferers have been handled with the revolutionary nanosynthetic bone graft OssDsign Catalyst, up from 1,000 sufferers handled in Could.
With 2,000 sufferers handled, OssDsign Catalyst continues to indicate exponential development from earlier data of 1,000 handled sufferers in Could and 500 sufferers handled in January.
“It’s nice to see how our orthobiologics enterprise continues its profitable commercialization. The accelerating development of OssDsign Catalyst reveals that our differentiated innovation has obtained a broad market acceptance,” stated Morten Henneveld, CEO of OssDsign.
OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of wholesome bone tissue in spinal fusion surgical procedures. The graft consists of a proprietary nanocrystalline construction which is resorbed and changed by new and wholesome bone tissue. The product was launched within the U.S. in August 2021. The market clearance within the U.S. is predicated on preclinical outcomes that surpass what is usually seen with different artificial bone grafts in probably the most demanding preclinical mannequin for spinal fusion – the Boden mannequin. OssDsign continues to speed up a sturdy program of gathering medical proof anchored by PROPEL, a U.S.-based multi-center potential spinal fusion registry and TOP FUSION, through which affected person enrolment was accomplished in April 2022.
For additional data, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, electronic mail: morten.henneveld@ossdsign.com
Licensed Adviser:
Erik Penser Financial institution AB is the corporate’s Licensed Adviser
Contact data: Erik Penser Financial institution AB, Field 7405, 103 91 Stockholm, Sweden
Telephone: +46 (0)8-463 80 00, electronic mail: certifiedadviser@penser.se
About OssDsign
OssDsign is a developer and world supplier of subsequent era bone alternative merchandise. Based mostly on leading edge materials science, the corporate develops and markets merchandise that assist the physique’s personal therapeutic capabilities and thereby enhance the medical consequence in a variety of orthopedic areas with excessive medical wants. With a product portfolio consisting of patient-specific implants for cranial surgical procedures and an off-the-shelf artificial bone graft for spine surgical procedures, OssDsign give sufferers again the life they deserve. The corporate has a powerful business presence within the U.S., Europe and chosen Asian nations. OssDsign’s share is traded on Nasdaq First North Development Market in Stockholm, Sweden.
Discussion about this post